[go: up one dir, main page]

MX2019001701A - Composicion farmaceutica de dosis fija que comprende mometasona y azelastina. - Google Patents

Composicion farmaceutica de dosis fija que comprende mometasona y azelastina.

Info

Publication number
MX2019001701A
MX2019001701A MX2019001701A MX2019001701A MX2019001701A MX 2019001701 A MX2019001701 A MX 2019001701A MX 2019001701 A MX2019001701 A MX 2019001701A MX 2019001701 A MX2019001701 A MX 2019001701A MX 2019001701 A MX2019001701 A MX 2019001701A
Authority
MX
Mexico
Prior art keywords
azelastine
pharmaceutical composition
fixed dose
dose pharmaceutical
composition including
Prior art date
Application number
MX2019001701A
Other languages
English (en)
Other versions
MX390789B (es
Inventor
Agarwal Piyush
Chaudhari Sunil
Rajurkar Suresh
R Dhuppad Ulhas
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BR102013000830A external-priority patent/BR102013000830A2/pt
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of MX2019001701A publication Critical patent/MX2019001701A/es
Publication of MX390789B publication Critical patent/MX390789B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica de dosis fija que comprende mometasona y azelastina. De forma particular, la presente invención proporciona una composición farmacéutica estable de dosis fija en la forma de un spray nasal que comprende mometasona o su sal y azelastina o su sal; y un proceso para preparar dicha composición, y su uso en el tratamiento de rinitis en un sujeto.
MX2019001701A 2012-12-06 2013-12-04 Composición farmacéutica de dosis fija que comprende mometasona y azelastina. MX390789B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3454MU2012 2012-12-06
BR102013000830A BR102013000830A2 (pt) 2013-01-11 2013-01-11 Composição farmacêutica para administração nasal, e, uso da mesma
PCT/IB2013/060638 WO2014087347A1 (en) 2012-12-06 2013-12-04 Fixed dose pharmaceutical composition comprising mometasone and azelastine

Publications (2)

Publication Number Publication Date
MX2019001701A true MX2019001701A (es) 2019-08-14
MX390789B MX390789B (es) 2025-03-21

Family

ID=50882873

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014003546A MX2014003546A (es) 2012-12-06 2013-12-04 Composicion farmaceutica de dosis fija que comprende mometasona y azelastina.
MX2019001701A MX390789B (es) 2012-12-06 2013-12-04 Composición farmacéutica de dosis fija que comprende mometasona y azelastina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014003546A MX2014003546A (es) 2012-12-06 2013-12-04 Composicion farmaceutica de dosis fija que comprende mometasona y azelastina.

Country Status (7)

Country Link
EP (1) EP2928302A1 (es)
EA (1) EA037259B1 (es)
MX (2) MX2014003546A (es)
MY (1) MY196902A (es)
PH (1) PH12015501179A1 (es)
WO (1) WO2014087347A1 (es)
ZA (1) ZA201503799B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109288790A (zh) * 2017-07-25 2019-02-01 健乔信元医药生技股份有限公司 鼻用医药组合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof

Also Published As

Publication number Publication date
MY196902A (en) 2023-05-09
ZA201503799B (en) 2016-02-24
EA201491769A1 (ru) 2015-06-30
EA037259B1 (ru) 2021-03-01
MX390789B (es) 2025-03-21
MX2014003546A (es) 2014-12-09
WO2014087347A1 (en) 2014-06-12
PH12015501179A1 (en) 2015-08-17
EP2928302A1 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
CR20150326A (es) Inhibidores de autotaxina
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
ECSP15007335A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CR20150629A (es) Compuestos químicos
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
ECSP15048122A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
CL2014001047A1 (es) Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.
NI201500096A (es) Compuesto químicos
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
MX2019001701A (es) Composicion farmaceutica de dosis fija que comprende mometasona y azelastina.